Skip to Content

Posts tagged with "Aging and Lifespan"

  • Aging and Lifespan

    Sirtris’s Compounds: Everyone Agrees?

    Christoph Westphal gave what by all accounts was a very interesting talk at the recent Bio-IT conference. And considering his track record in company formation, he’s well worth listening to. But concerning the recent controversy over the compounds and results from his most recent success (Sirtris), I found this part of his speech. . .well… Read More
  • Aging and Lifespan

    Take These?

    A reader sends along a note about this patent application from the University of Rochester. The inventor, David Goldfarb, seems to have used an assay (the subject of a previous application) to screen a library of commercially available compounds for potential life-extending properties in model organisms. Here’s some detail on the screen from… Read More
  • Aging and Lifespan

    Rapamycin for Alzheimer’s?

    Last summer a paper was published (PDF) showing rapamycin dosing appeared to lengthen lifespan in mice. (In that second link, I went more into the background of rapamycin and TOR signaling, for those who are interested). Now comes word that it also seems to prevent cognitive deficits in a mouse model of Alzheimer’s. The PDAPP… Read More
  • Aging and Lifespan

    The Problem With Research on Aging

    Nature has a review of a new book on the anti-aging field, Eternity Soup by Greg Critser, and I found this part very instructive. The same things apply to several other therapeutic areas where people see fast money to be made: Critser’s methodical portrayal of a host of anti-ageing practitioners reveals some fascinating people who… Read More
  • Aging and Lifespan

    BioTime’s Cellular Aging Results

    A small company called BioTime has gotten a lot of attention in the last couple of days after a press release about cellular aging. To give you an idea of the company’s language, here’s a quote: “Normal human cells were induced to reverse both the “clock” of differentiation (the process by which an embryonic stem… Read More
  • Aging and Lifespan

    A GSK/Sirtris Wrap-Up

    Nature Biotechnology weighs in on the GSK/Sirtris controversy. They have a lot of good information, and I’m not just saying that because someone there has clearly read over the comments that have showed up to my posts on the subject. The short form: The controversy over Sirtris drugs reached a tipping point in January with… Read More
  • Aging and Lifespan

    A Storm in a Teacup

    So says GlaxoSmithKline CEO Andrew Witty about the Sirtris controversy – see this Forbes story for more. I hope he’s right. I actually would like to see good things come out of sirtuin research – the biology’s clearly interesting enough. And I would like to think that GSK didn’t blow $720 million, because we could… Read More
  • Aging and Lifespan

    GSK and Sirtris: A Bit More

    Nature has a short item on the Pfizer paper that questions the reproducibility of some key sirtuin work (covered here and here). There are some good points to temper the pessimism. Leonard Guarente of MIT, a key pioneer in the field, says: “. . . that the latest findings are neither surprising nor worrisome. The… Read More
  • Aging and Lifespan

    Sirtuin Scenarios

    So, after reading what Pfizer has to say about Sirtris (and by extension, about GlaxoSmithKline’s heavy investment in them), let’s go over the possibilities. What happened, and what’s going on? We’ll start out with the first branch point: either Pfizer (and Amgen) are right that there’s trouble with the Sirtris assays… Read More
  • Aging and Lifespan

    The Sirtris Compounds: Worthless? Really?

    As followers of the drug industry know, GlaxoSmithKline famously paid $720 million to buy Sirtris Pharmaceuticals in 2008. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of press (some accurate, some scrambled). I’ve been following the story with interes… Read More
...567...